The study of droperidol on prevention of emesis from cannabinoid hyperemesis syndrome

The company Mercy Health Ohio is enrolling patients into the clinical trial investigating Droperidol on Prevention of Cannabis Hyperemesis Syndrome (DOPE).

The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.

The trial is designed to enroll male and female 18 Years and older and is being conducted in the Mercy Health - Austintown, Austintown, Ohio, United States; St Elizabeth Boardman Hospital, Boardman, Ohio, United States; St. Joseph-Warren Hospital, Warren, Ohio, United States; St Elizabeth Youngstown Hospital, Youngstown, Ohio, United States.

The study start date is December 2, 2021.

This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05244460.

Clinical Research News

Upcoming Clinical Trials

3